Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108619 | 0.84 | CYP2A13 (0.69) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL11193326 | 0.77 | CYP2A13 (0.75) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL28662303 | 0.76 | CYP2A13 (0.59) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL1328958 | 0.76 | CYP2A13 (0.47) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL13849993 | 0.75 | CYP2A13 (0.71) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL4097834 | 0.74 | CYP2A13 (1.00) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL7114819 | 0.74 | KDM4E (0.64) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL10235392 | 0.74 | NCF1 (0.71) | CYP2A13ALDH1A1CXCR4HSD17B10KDM4E | |
| SCHEMBL28852963 | 0.74 | CYP2A13 (0.75) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 | |
| SCHEMBL4105461 | 0.74 | CYP2A13 (1.00) | CYP2A13ALDH1A1KMT2AMEN1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962624-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | UNIVERSITY OF KANSAS (US) | 2014-02-13 | — | — | US | disclosed |
| US-8598165-B2 | Morpholines as selective inhibitors of cytochrome P450 2A13 | UNIVERSITY OF KANSAS (US) | 2013-12-03 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137592-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885ALDH1A1 120/4885KMT2A 1372/4885 |
| US-20140045851-A1 | MORPHOLINES AS SELECTIVE INHIBITORS OF CYTOCHROME P450 2A13 | CYP1A2, CYP2D6, CYP1A1 | CYP2A13 6/4885ALDH1A1 120/4885KMT2A 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.